Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Closes $72M in Debt and Equity Funding

NEW YORK – Metabolon announced on Wednesday that it had closed on $72 million in combined debt and equity financing.

In a statement, company President and CEO Rohan Hastie said that it planned to use the funding to grow its client base and further its R&D programs using machine learning for biomarker discovery and precision medicine.

The round included new investor Perceptive Advisors as well as existing investors including EW Healthcare Partners.

Morrisville, North Carolina-based Metabolon also announced that it had appointed Robert Cascella, chief business leader, precision diagnostics and executive vice president at Phillips, to its board of directors.

Last month, Metabolon said it had entered into a multiyear drug development alliance with Germany's Merck KGaA.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.